Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

9 Customer Reviews

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnvR|lYUUN3ME2wMlAxODByM{CzJO69VQ>? M3O0c3NCVkeHUh?=
MONO-MAC-6 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\5PG9RUUN3ME2wMlAxPDF6IN88US=> M{f2SXNCVkeHUh?=
ALL-PO NEj0[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEOxPFQh|ryP NYLyXopbW0GQR1XS
NKM-1 NV\obWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEe0NVYh|ryP MYDTRW5ITVJ?
CGTH-W-1 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMkWwNlIh|ryP NGH4OFdUSU6JRWK=
BB65-RCC NGriTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNEewO|Mh|ryP MnzBV2FPT0WU
NOS-1 NXzXOZBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y0T2lEPTB;MD61OlM3KM7:TR?= M4DZeHNCVkeHUh?=
SH-4 M4TPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNkW2NVMh|ryP MVHTRW5ITVJ?
HOP-62 NIPuSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwOEWwPFgh|ryP MVLTRW5ITVJ?
HCC2998 NXLtSJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOEi4NVgh|ryP NVnKRlR3W0GQR1XS
GDM-1 M{[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\wXGlEPTB;MD65NFY6QCEQvF2= M1rNSXNCVkeHUh?=
KM12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwMEKwPVgh|ryP MoLvV2FPT0WU
LB2518-MEL NXPON3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMkC4NFkh|ryP NUPlZY9WW0GQR1XS
NCI-H1436 NWn6Wll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwMkG2O|gh|ryP NUjneXhRW0GQR1XS
EM-2 NFOwdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwM{W1O|gh|ryP M4f5cnNCVkeHUh?=
LAMA-84 M3XxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TCO2lEPTB;MT6zO|Y1QCEQvF2= NEjZOZpUSU6JRWK=
KG-1 M4\QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPQTWM2OD1zLkS3PVM2KM7:TR?= NWDN[5plW0GQR1XS
A388 NE\h[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jqS2lEPTB;MT61PVE3PSEQvF2= NETOeI9USU6JRWK=
no-10 NYXsOoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe2NVF6UUN3ME2xMlYyPzJ4IN88US=> NULy[YYxW0GQR1XS
SF126 NWfIbok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNkO4NVIh|ryP M4G0eHNCVkeHUh?=
MEG-01 M334cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwOEC5PEDPxE1? NFrabmZUSU6JRWK=
A3-KAW NUnlc3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwOEi0NkDPxE1? NYK4RpdyW0GQR1XS
D-247MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;mVVJKSzVyPUKuNVQ1QCEQvF2= MYnTRW5ITVJ?
OVCAR-4 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLemlEPTB;Mj6yNVM6OyEQvF2= NULWSWxOW0GQR1XS
NCI-SNU-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn1fWRKSzVyPUKuN|E3OiEQvF2= NH\rXWhUSU6JRWK=
NCI-H2171 NI\SUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC0XGJKSzVyPUKuN|k4PjRizszN MWXTRW5ITVJ?
SIG-M5 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJwNEKyOFIh|ryP M2nUU3NCVkeHUh?=
BE-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TaV2lEPTB;Mj62PVYxQSEQvF2= M1P0V3NCVkeHUh?=
K052 M2\OZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXvTVdKSzVyPUKuO|Q3OTZizszN MXPTRW5ITVJ?
L-540 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3dVlKSzVyPUKuO|U4QDlizszN M3iwWnNCVkeHUh?=
KMOE-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnFc4NKSzVyPUKuPFE{PSEQvF2= M1Lz[3NCVkeHUh?=
MFH-ino M{Lkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;Ze2lEPTB;Mj65NlE5PSEQvF2= NGTyN5JUSU6JRWK=
HL-60 M1LPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3O2lEPTB;Mz6wOlI6QSEQvF2= NGDSfI5USU6JRWK=
HCC2218 NYD6[|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jwWWlEPTB;Mz6xNlAxOyEQvF2= MlflV2FPT0WU
TE-5 M4q0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rRcGlEPTB;Mz6xN|E3OiEQvF2= NUn2T3M1W0GQR1XS
MZ1-PC MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO1VHFKSzVyPUOuOFc2ODlizszN Mn;qV2FPT0WU
MRK-nu-1 NXzKPIVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj2XGpKSzVyPUOuOlE1PjhizszN NHXQbGlUSU6JRWK=
MZ7-mel NGTjNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxcmRKSzVyPUOuOlYxQTlizszN NXnvWndnW0GQR1XS
BC-1 M4S5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLwTWM2OD1|Lke0NFIh|ryP MUXTRW5ITVJ?
ST486 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7wdHRKSzVyPUOuPFM3PzNizszN NXjEPGdTW0GQR1XS
KS-1 M1e4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O4W2lEPTB;Mz64PFE6QCEQvF2= MoLwV2FPT0WU
SK-NEP-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiwTm5rUUN3ME20MlE3QDF3IN88US=> NUHZSlV4W0GQR1XS
BC-3 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;LTWM2OD12LkKzN|kyKM7:TR?= MUTTRW5ITVJ?
NCI-H1581 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwMki3PVgh|ryP M4i2dnNCVkeHUh?=
MHH-PREB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHoXWtKSzVyPUSuOFA1QDRizszN M1ex[HNCVkeHUh?=
NOMO-1 NUX0NGljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRwNEi5NFUh|ryP NH21ZplUSU6JRWK=
QIMR-WIL M1PJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwMEeyPVQh|ryP MWLTRW5ITVJ?
SF539 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjnN2dKSzVyPUWuNVMzOjdizszN M2LDXHNCVkeHUh?=
TE-12 NGH3T|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrqdmhwUUN3ME21MlI1QTJ7IN88US=> MkPVV2FPT0WU
NCI-H510A M3vYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33iTGlEPTB;NT60NVY5PSEQvF2= MXfTRW5ITVJ?
JAR Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZOmlEPTB;NT61NFgzPCEQvF2= MX\TRW5ITVJ?
no-11 NE\POnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwN{O1Olgh|ryP NEDCbphUSU6JRWK=
BV-173 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwOUW2PFIh|ryP M4Hrc3NCVkeHUh?=
SR M4nNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO2e4x7UUN3ME22MlAxPjd6IN88US=> NEHJdFJUSU6JRWK=
MOLT-16 NXnYOY42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjGTWM2OD14LkK1NlY3KM7:TR?= NWL5OJBXW0GQR1XS
MZ2-MEL NUC4SIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfuTWM2OD14LkOxPFM6KM7:TR?= M{TRV3NCVkeHUh?=
SW954 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD14LkS1PFY3KM7:TR?= M3LKbXNCVkeHUh?=
ML-2 NGLrbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHKTWM2OD14LkWyPFQ6KM7:TR?= MnP3V2FPT0WU
OCI-AML2 NUDWZ3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D2eGlEPTB;Nj62NVA3OiEQvF2= MXTTRW5ITVJ?
SIMA MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[2fW5yUUN3ME23MlAxOTBzIN88US=> Moq5V2FPT0WU
DOHH-2 NHfORlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;LNJdrUUN3ME23MlA2Pjd4IN88US=> NWDSW45GW0GQR1XS
697 NWj1R416T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrsdpl1UUN3ME23MlA2QTh7IN88US=> MlX4V2FPT0WU
NB1 M2G4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTdwNEC0NFch|ryP NVXBWFFLW0GQR1XS
D-392MG NFGyO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwNkK2OlMh|ryP MYXTRW5ITVJ?
ES8 NYrzdXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2fGFKSzVyPUeuO|Y2ODNizszN MnW3V2FPT0WU
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwOES1NVEh|ryP Ml\xV2FPT0WU
IST-MEL1 NHrGOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLKTWM2OD16LkSwNFAzKM7:TR?= Mm\6V2FPT0WU
NB14 M3rZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLPTWM2OD16Lk[zNVM{KM7:TR?= M3faWnNCVkeHUh?=
HD-MY-Z NXjnSpM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRThwNkO3OFYh|ryP NHzRW4tUSU6JRWK=
TE-10 M3HweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Fc3VKSzVyPUiuO|Y{PTNizszN NYjoPJg3W0GQR1XS
LC-1F NHnqSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfBSFNiUUN3ME25MlExQDN2IN88US=> M3fVcHNCVkeHUh?=
OS-RC-2 NYn0SpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlixTWM2OD17LkGxNlQ{KM7:TR?= NWnTTIo3W0GQR1XS
NCI-SNU-16 M1fIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTSTWM2OD17LkKxNFI3KM7:TR?= MVPTRW5ITVJ?
SHP-77 M4\FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHmTWM2OD17LkexOlYzKM7:TR?= M3OxWHNCVkeHUh?=
A4-Fuk MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH65bmFKSzVyPUmuO|U3OSEQvF2= M3roVXNCVkeHUh?=
NB6 NVXhd4I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rsZWlEPTB;OT63OlAzQSEQvF2= MnTGV2FPT0WU
JiyoyeP-2003 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLNTWM2OD1zMD60O|Q2KM7:TR?= NHK2SGRUSU6JRWK=
DMS-114 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFyLkW0OFEh|ryP NXmwSoFnW0GQR1XS
NB7 M4r1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD1zMD63OVI3KM7:TR?= MWfTRW5ITVJ?
NCI-H747 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu3VVZKSzVyPUGxMlEzOTZizszN MVnTRW5ITVJ?
HH MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILmPXdKSzVyPUGxMlM5PzZizszN NVvTfmplW0GQR1XS
EW-18 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxdmJKSzVyPUGxMlkxPDRizszN M3vTXHNCVkeHUh?=
CHP-126 NWLH[G1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLNRmppUUN3ME2xNU46PzN6IN88US=> NXnjV4pWW0GQR1XS
NTERA-S-cl-D1 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG3fVZKSzVyPUGyMlAzPzhizszN Mln2V2FPT0WU
DEL Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF{LkC5PFUh|ryP M1fRbnNCVkeHUh?=
LU-139 M1XScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHCdpBjUUN3ME2xNk42PDF|IN88US=> NVHFTYl3W0GQR1XS
P30-OHK M4i1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTSO5FKSzVyPUGyMlU1PzlizszN Ml;aV2FPT0WU
NCI-H1522 NIfzPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH35[XBKSzVyPUGyMlc1PiEQvF2= MYHTRW5ITVJ?
NCI-H1299 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF|LkK5NVEh|ryP MXTTRW5ITVJ?
UACC-257 NVH5N2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL4TWM2OD1zMz61NVI3KM7:TR?= MYnTRW5ITVJ?
Calu-6 NGjRR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj4fplVUUN3ME2xN{43ODR4IN88US=> M3nm[HNCVkeHUh?=
NCI-H1882 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PvbmlEPTB;MUOuPFU2PSEQvF2= NUS5RpBDW0GQR1XS
BB30-HNC MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn5dGlKSzVyPUG0MlA3ODlizszN NHm3V2VUSU6JRWK=
ES1 M4n5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXWTWM2OD1zND6xOVUyKM7:TR?= MlvEV2FPT0WU
NCI-H1694 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF2LkS4NVEh|ryP NX3UeItIW0GQR1XS
IST-SL1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTLNm0xUUN3ME2xOE46PjF4IN88US=> Mkf5V2FPT0WU
ECC4 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO3TWM2OD1zNT6wOVU5KM7:TR?= M1W4cHNCVkeHUh?=
MDA-MB-134-VI NWi1VJJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF3LkSxN|Eh|ryP M17wc3NCVkeHUh?=
SCH NEHYeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XzbWlEPTB;MUWuOFczQCEQvF2= MmOwV2FPT0WU
SK-N-FI M2T6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPoSYRFUUN3ME2xOU43PTN2IN88US=> MULTRW5ITVJ?
HDLM-2 NXKwS21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fzUWlEPTB;MU[uNFcyPCEQvF2= M2HLOHNCVkeHUh?=
Ramos-2G6-4C10 NFTUSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF4LkGyPVch|ryP M1PlSnNCVkeHUh?=
EW-24 NX;5WWFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7kTWM2OD1zNj6xOlYyKM7:TR?= NFXiUWxUSU6JRWK=
NCI-H2141 NUjlR4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyemlEPTB;MU[uNVg6KM7:TR?= NVy5XW13W0GQR1XS
LC4-1 M{m0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\seGJnUUN3ME2xOk43OTF7IN88US=> MoX2V2FPT0WU
HT-144 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37BeGlEPTB;MUeuNFA3KM7:TR?= MULTRW5ITVJ?
SK-MEL-1 NUXTUmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF5LkCwO|Ih|ryP MnvJV2FPT0WU
SCC-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5LkG2N|gh|ryP M{HWd3NCVkeHUh?=
C8166 NYfZcFBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrvXWhKSzVyPUG3MlY5OzNizszN MYLTRW5ITVJ?
GOTO MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5LkizOFQh|ryP MWnTRW5ITVJ?
COR-L279 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF6LkGzOlIh|ryP NWXaTXlMW0GQR1XS
K-562 NETw[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vqfmlEPTB;MUiuO|E1OyEQvF2= NEnlWIxUSU6JRWK=
ES3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfCZVhlUUN3ME2xPE45ODRzIN88US=> NYjwTlJLW0GQR1XS
LU-165 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXzO3JKSzVyPUG5MlcxODhizszN NIrEVHVUSU6JRWK=
KM-H2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGwW3dKSzVyPUKwMlMyQDRizszN MlfVV2FPT0WU
RL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDKRmNKSzVyPUKwMlk3QTJizszN MnvGV2FPT0WU
EW-3 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H1[WlEPTB;MkGuNVg5QSEQvF2= MmjpV2FPT0WU
A101D MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPvblhKSzVyPUKxMlM4PTJizszN MVXTRW5ITVJ?
HUTU-80 NIGzNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJzLkO5OFYh|ryP MorZV2FPT0WU
NCI-H23 NWrkZnpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKwWlNKSzVyPUKxMlM6QTJizszN MVnTRW5ITVJ?
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYra[lBQUUN3ME2yNU41PDB|IN88US=> NIq4OVBUSU6JRWK=
LB373-MEL-D NF7JZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJzLkW2NVUh|ryP MkTxV2FPT0WU
TE-8 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJzLk[zPVQh|ryP Moj1V2FPT0WU
TE-9 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i4SGlEPTB;MkGuPFUyOyEQvF2= NILoZpFUSU6JRWK=
Daudi MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHwcVJKSzVyPUKxMlk{ODRizszN Ml7VV2FPT0WU
D-542MG MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ{LkCyOVYh|ryP NEfMO4lUSU6JRWK=
U-698-M MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7QXGFuUUN3ME2yNk41PjB|IN88US=> NHHDd3NUSU6JRWK=
ES6 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorUTWM2OD1{Mj63N|Y3KM7:TR?= NIHHWo9USU6JRWK=
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LUbmlEPTB;MkOuPFg6PyEQvF2= NVu0[oUzW0GQR1XS
ECC12 NGTxOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H5NGlEPTB;MkSuNlgxOyEQvF2= MmHNV2FPT0WU
C2BBe1 NVLNenVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ2LkOyN|kh|ryP NX\BT4dXW0GQR1XS
IST-SL2 M1vodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\GVplNUUN3ME2yOE41OzZ{IN88US=> Mo[4V2FPT0WU
DJM-1 NITET|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP1TWM2OD1{ND61NlIyKM7:TR?= NWG4TZJkW0GQR1XS
DMS-153 NWTEe2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\iWZlzUUN3ME2yOE45PjF2IN88US=> MXTTRW5ITVJ?
NB13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uyNWlEPTB;MkWuNFI3PSEQvF2= NH7JOHVUSU6JRWK=
SK-N-DZ NID0RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ4LkO0NVQh|ryP MoLEV2FPT0WU
COR-L88 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLnOVhpUUN3ME2yOk42Pzl4IN88US=> NUX3Tm5TW0GQR1XS
LU-65 M{Cyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TMU2lEPTB;Mk[uPFU{PSEQvF2= NG\KcWxUSU6JRWK=
TGBC1TKB NF3IWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D3R2lEPTB;Mk[uPVgzQCEQvF2= MUfTRW5ITVJ?
THP-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvyTWM2OD1{Nz6yNVQyKM7:TR?= M1\CeXNCVkeHUh?=
ONS-76 NYPVVnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C0cGlEPTB;MkeuN|MzKM7:TR?= NGe4O|JUSU6JRWK=
LC-2-ad NGfMSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ5Lk[yN|Eh|ryP Ml3jV2FPT0WU
EW-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ7LkG3OFYh|ryP NVe4b3ZXW0GQR1XS
MS-1 NF3LW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\6eVJKSzVyPUOwMlczPzhizszN MljJV2FPT0WU
NCI-H2227 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjYTWM2OD1|MD65PFA3KM7:TR?= MULTRW5ITVJ?
LXF-289 NYrpXIlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LJSmlEPTB;M{GuOFQ6OiEQvF2= NWfUU3ExW0GQR1XS
MC116 M3T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPRTJZKSzVyPUOyMlA5OjZizszN MofsV2FPT0WU
EVSA-T NFi5VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTN{LkK1PFUh|ryP M{npcHNCVkeHUh?=
CTB-1 NUXndnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN|LkGxNFEh|ryP NVXLeXlWW0GQR1XS
COLO-320-HSR MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zVbmlEPTB;M{OuNVYxOyEQvF2= NEfBR|JUSU6JRWK=
NCI-H2196 NYHtS2E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLQeGplUUN3ME2zN{4zPTV5IN88US=> NGXF[XdUSU6JRWK=
LB2241-RCC M1Tj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELrT2tKSzVyPUOzMlMyOzVizszN NWjOcFF4W0GQR1XS
LS-513 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:0fm1xUUN3ME2zN{45PjN6IN88US=> MlHTV2FPT0WU
LP-1 NX\VclBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN|Lkm5OVYh|ryP NW[0SXl3W0GQR1XS
A253 NYP3OVBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHvSVdOUUN3ME2zOE4zOjl4IN88US=> NUP0XmtIW0GQR1XS
SK-MM-2 NHz1OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:5TWM2OD1|ND65OFUyKM7:TR?= NEjNeFBUSU6JRWK=
NCI-H1963 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN3LkOwO|Ih|ryP MlPnV2FPT0WU
MMAC-SF NYewSJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq3W2hyUUN3ME2zOU45Pzh3IN88US=> MWrTRW5ITVJ?
LB831-BLC M4ryXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme4TWM2OD1|Nj6wOlU1KM7:TR?= NXm0c4hEW0GQR1XS
WSU-NHL NWLXPZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\M[mlEPTB;M{[uNVY1KM7:TR?= MlLmV2FPT0WU
CESS NXPVbWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTOTY1KSzVyPUO2MlI5PDhizszN NVr3NHVqW0GQR1XS
NEC8 M1y2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN4LkW4N|Uh|ryP M3[2SnNCVkeHUh?=
KNS-42 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4emtKSzVyPUO3MlEzOzdizszN MlPDV2FPT0WU
MHH-CALL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETTeVZKSzVyPUO3MlE5OjFizszN M37Yc3NCVkeHUh?=
K5 M4n5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f0PWlEPTB;M{iuOFMh|ryP NX7CU3huW0GQR1XS
CP66-MEL Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD1|OT6wO|M{KM7:TR?= NFvjdVlUSU6JRWK=
OPM-2 NXfPXINIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN7Lki0N|Ih|ryP NVLkNIw6W0GQR1XS
IST-MES1 NEi4NpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGcpVKSzVyPUSwMlMxQTZizszN Mn25V2FPT0WU
EC-GI-10 NWjhPWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;UTWM2OD12MT61PFA2KM7:TR?= MmTrV2FPT0WU
CTV-1 M1y0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXyOHpnUUN3ME20Nk45PDB4IN88US=> MWfTRW5ITVJ?
DG-75 NUnQ[5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR|Lke1PVUh|ryP MkPvV2FPT0WU
KNS-81-FD NYHjTFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XR[2lEPTB;NEWuOFA2QCEQvF2= NFn6boFUSU6JRWK=
NCI-H82 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR3LkW3OVgh|ryP MWrTRW5ITVJ?
RPMI-8866 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR4LkG4O|Mh|ryP MlPIV2FPT0WU
ACN NUfUW|RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvVTWM2OD12Nj60N|Qh|ryP MU\TRW5ITVJ?
NCI-H1395 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HHRWlEPTB;NE[uOFc2PiEQvF2= MUfTRW5ITVJ?
NCI-H209 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTR5LkG0NFUh|ryP NVPvOVRJW0GQR1XS
TGW M2nle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DVVWlEPTB;NEmuNFc6OSEQvF2= NEmyVJVUSU6JRWK=
NCI-H748 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonYTWM2OD12OT60O|U{KM7:TR?= NV7JcnNpW0GQR1XS
EKVX NUmy[3FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnwW|NLUUN3ME20PU43PjJ6IN88US=> NETlWGdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID